Detail akcie CarMat online

Business Summary: Carmat SA, formerly known as Carmat SAS is a France-based company engaged in the development and production of heart prosthesis. The Company is developing an orthotopic and biocompatible artificial heart which works like a natural heart, and which is hydraulically activated. It specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnosis system. The Company formed a network of partnerships with hospitals and various scientific companies, such as The Georges Pompidou European Hospital, The Marie Lannelongue Surgical Center, The Hospital Charles Nicolle of Rouen, Dedienne Sante, PaxiTech, Vignal Artru Industries, French Vessels, and Blood Institute, Laboratoire de Recherche Biochirurgicale and others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Carmat SA revenues increased from EUR2.8M to EUR7M. Net loss applicable to common stockholders decreased 5% to EUR51.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects TOTAL OPERATING INCOME increase of 44% to EUR12.5M (income), of current assets: impairment decrease of 21% to EUR9.1M (expense).